{
  "source": "PA-Med-Nec-Filsuvez.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2337-2\nProgram Prior Authorization/Medical Necessity\nMedication Filsuvez® (birch triterpenes) topical gel\nP&T Approval Date 4/2024, 4/2024\nEffective Date 7/1/2025\n1. Background:\nFilsuvez (birch triterpenes) topical gel is indicated for the treatment of wounds associated\nwith dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6\nmonths of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Filsuvez will be approved based on all of the following criteria:\na. Patient is at least 6 months of age and older\n-AND-\nb. One of the following diagnoses:\n(1) Dystrophic epidermolysis bullosa (DEB)\n-OR-\n(2) Junctional epidermolysis bullosa (JEB)\n-AND-\nc. Submission of medical records (e.g., chart notes, laboratory values) confirming a\ngenetic mutation associated with DEB or JEB (i.e., COL7A1, LAMA3, LAMB3, LAMC2,\nCOL17A1, ITGA6, ITGB4, ITGA3)\n-AND-\nd. Patient has at least one partial thickness wound that meets all of the following criteria:\n(1) 10-50 cm2 in size\n-AND-\n(2) Present for at least 3 weeks\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(3) Adequate granulation tissue\n-AND-\n(4) Excellent vascularization\n-AND-\n(5) No evidence of active wound infection\n-AND-\n(6) No evidence or history of basal or squamous cell carcinomas (SCC)\n-AND-\ne. Prescribed by, or in consultation with, a dermatologist with expertise in the treatment of\nepidermolysis bullosa (EB)\n-AND-\nf. Patient is not receiving Filsuvez in combination with Vyjuvek (beremagene\ngeperpavec-svdt) on the same wound(s)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Filsuvez will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Filsuvez therapy (e.g., complete wound\nclosure, reduction in wound size, decrease in procedural pain, less frequent dressing\nchanges, decreased total body wound burden)\n-AND-\nb. Wound (s) being treated meet all of",
    "apy (e.g., complete wound\nclosure, reduction in wound size, decrease in procedural pain, less frequent dressing\nchanges, decreased total body wound burden)\n-AND-\nb. Wound (s) being treated meet all of the following criteria:\n(1) Adequate granulation tissue\n-AND-\n(2) Excellent vascularization\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(3) No evidence of active wound infection\n-AND-\n(4) No evidence or history of basal or squamous cell carcinomas (SCC)\n-AND-\nc. Filsuvez is prescribed by, or in consultation with, a dermatologist with expertise in the\ntreatment of epidermolysis bullosa (EB)\n-AND-\nd. Patient is not receiving Filsuvez in combination with Vyjuvek (beremagene\ngeperpavec-svdt) on the same wound(s)\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n4. References:\n1. Filsuvez [package insert]. Boston, MA: Chiesi Global Rare Diseases; May 2024.\n2. Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch\ntriterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind\nphase of the EASE study. Br J Dermatol. 2023;188(1):12-21.\n3. Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. Molecular genetics\nof the junctional and hemidesmosomal variants. J Med Genet. 2006;43(8):641-652.\nProgram Prior Authorization/Medical Necessity - Filsuvez (birch triterpenes)\nChange Control\n4/2024 New program\n4/2025 Annual review with no changes to criteria. Updated references.\n© 2025 UnitedHealthcare Servi",
    "ior Authorization/Medical Necessity - Filsuvez (birch triterpenes)\nChange Control\n4/2024 New program\n4/2025 Annual review with no changes to criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}